Most studies of obstructive salivary gland disease have reported only statistical aspects, surgical operations, and prescriptions and have simulated the phenomena occurring in the salivary glands and ductal tissues. However, no direct lesion treatments involving drug-eluting stents have been used to reduce salivary pooling induced by inflammation. In this study, a biodegradable polymer polycaprolactone (PCL)-based antibiotic-eluting stent was developed to treat recurrent obstructive salivary gland disease. The structure's diameter was designed after consideration of the human anatomical structure, and the data were processed in a form suitable for three-dimensional (3D) printing via computer-aided design and manufacturing. After the proper mixing conditions of the antibiotics and PCL were ensured, the optimized printing conditions were secured and the stent was successfully printed with the original lumen size diameter maintained. Amoxicillin and cefotaxime, the antibiotics loaded in this study, did not lose their original antimicrobial activity under the 3D printing process and were effectively released from the constructs for verification of the antimicrobial activity against the causative bacteria according to their concentrations. In addition, antibiotic-eluting stents fabricated in a mesh-like network form were proven stable and capable of sustained release, thereby demonstrating the possibility of treating recurrent obstruction salivary gland disease.
Keywords: 3D printing; antibiotics; drug-eluting; obstructive salivary gland disease; stent.